Jeong J H, Lee J-I, Ju M K, Joo D J, Huh K H, Kim M S, Kim J Y, Cho Y, Kim Y S
Research Institute for Transplantation, Yonsei University, Graduate Program of Nanoscience and Technology, Department of Surgery, Yonsei University College of Medicine, Yonsei University, Seoul, South Korea.
Transplant Proc. 2010 Apr;42(3):907-10. doi: 10.1016/j.transproceed.2010.02.044.
Donor scarcity is a major obstacle for clinical islet transplantation. Hence, the effective use of the limited number of available islets is necessary for successful islet transplantation. We have developed a new technology that could produce pseudo-islets. Morphologic and functional evaluation was performed to test the feasibility of using these cells for transplantation. A 3-step procedure known as disaggregation-expansion-reaggregation (DER) was employed for pseudo-islet preparation. Islets isolated from 200 to 250-g male Lewis rats by collagenase digestion were separated into single cells by trypsinization. These pancreatic endocrine cells (PECs) were expanded by serial passages in culture before being aggregated at a high cell-density in a suspended state. After DER, cells were morphologically analyzed over time, and gene expression evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). Through expansion by passage for 2 weeks in continuous cultures, approximately 1 million PECs were recovered after aggregation. By phase-contrast microscopy, they presented with spherical shapes and similar sizes compared with naïve islets (50-800 microm). RT-PCR results indicated expression of insulin, glucagon, and pancreatic and duodenal homeobox gene 1, which were observed in primary isolated islets as well. The insulin secretion capacity of pseudo-islets was confirmed by enzyme-linked immunosorbent assay. In conclusion, PECs treated with DER showed potential to serve as a cell source for pseudo-islet generation after in vitro cellular expansion. These cells were both morphologically and genetically similar to naïve islets. Our new technique could be a potential method to overcome the scarcity of donor islets in the near future.
供体稀缺是临床胰岛移植的主要障碍。因此,有效利用有限数量的可用胰岛对于胰岛移植的成功至关重要。我们开发了一种能够产生伪胰岛的新技术。进行了形态学和功能评估,以测试使用这些细胞进行移植的可行性。一种称为解离 - 扩增 - 重聚集(DER)的三步程序用于制备伪胰岛。通过胶原酶消化从200至250克雄性Lewis大鼠分离的胰岛经胰蛋白酶消化分离成单个细胞。这些胰腺内分泌细胞(PEC)在培养中通过连续传代进行扩增,然后在悬浮状态下以高细胞密度聚集。DER处理后,随时间对细胞进行形态学分析,并通过逆转录聚合酶链反应(RT-PCR)评估基因表达。通过在连续培养中传代扩增2周,聚集后回收了约100万个PEC。相差显微镜观察显示,它们呈现球形,大小与天然胰岛(50 - 800微米)相似。RT-PCR结果表明胰岛素、胰高血糖素和胰腺十二指肠同源盒基因1的表达,这些基因在原代分离的胰岛中也有观察到。通过酶联免疫吸附测定证实了伪胰岛的胰岛素分泌能力。总之,经DER处理的PEC在体外细胞扩增后显示出作为伪胰岛生成细胞来源的潜力。这些细胞在形态和基因上均与天然胰岛相似。我们的新技术可能是在不久的将来克服供体胰岛稀缺问题的一种潜在方法。